Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
1,292
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Circulating miR-448 acts as a potential diagnostic biomarker for multiple myeloma

Dan Chena Department of Central Laboratory, The Affiliated Hospital of Chengde Medical College, Chengde, People’s Republic of China;b Department of Laboratory Medicine, Wusong Branch, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-2396-0314View further author information
ORCID Icon,
Teng Chena Department of Central Laboratory, The Affiliated Hospital of Chengde Medical College, Chengde, People’s Republic of ChinaView further author information
,
Lihong Wangc Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde, People’s Republic of ChinaView further author information
,
Zhihua Zhangc Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde, People’s Republic of ChinaView further author information
&
Enhong Xinga Department of Central Laboratory, The Affiliated Hospital of Chengde Medical College, Chengde, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 847-852 | Published online: 08 Aug 2022

References

  • Li J, Zhang M, Wang C. Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. J Clin Lab Anal. 2020;34(6):e23233.
  • Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl 1):62–65.
  • Riccomi G, Fornaciari G, Giuffra V. Multiple myeloma in paleopathology: a critical review. Int J Paleopathol. 2019;24:201–212.
  • Ahn JS, Okal R, Vos JA, et al. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. J Clin Pathol. 2017;70(9):775–780.
  • Xiao LI, Lin F, Xiao R, et al. Multiple myeloma-associated skin light chain amyloidosis: a case of misdiagnosis. Oncol Lett. 2016;11(6):3617–3620.
  • Chan HSH, Chen CI, Reece DE. Current review on high-risk multiple myeloma. Curr Hematol Malig Rep. 2017;12(2):96–108.
  • Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972.
  • Correia de Sousa M, Gjorgjieva M, Dolicka D, et al. Deciphering miRNAs’ action through miRNA editing. Int J Mol Sci. 2019;20(24):6249.
  • Huang W. MicroRNAs: biomarkers, diagnostics, and therapeutics. Methods Mol Biol. 2017;1617:57–67.
  • Li P, Teng F, Gao F, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute ischemic stroke. Cell Mol Neurobiol. 2015;35(3):433–447.
  • Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59(1):S1–S6.
  • Yuan X, Ma R, Yang S, et al. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Cell Cycle. 2019;18(14):1660–1669.
  • Lou Q, Liu R, Yang X, et al. miR-448 targets IDO1 and regulates CD8(+) T cell response in human colon cancer. J Immunother Cancer. 2019;7(1):210.
  • Jin J, Wu Y, Zhou D, et al. Mir448 targets Rab2B and is pivotal in the suppression of pancreatic cancer. Oncol Rep. 2018;40(3):1379–1389.
  • Wu X, Tang H, Liu G, et al. miR-448 suppressed gastric cancer proliferation and invasion by regulating ADAM10. Tumour Biol. 2016;37(8):10545–10551.
  • Li T, Yuan J, Lai Y, et al. The antitumor effect of miR-448 in epithelial ovarian cancer. Transl Cancer Res. 2020;9(8):4922–4930.
  • Jiang X, Zhou Y, Sun AJ, et al. NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1. J Cell Physiol. 2018;233(11):8558–8566.
  • Fan CB, Yan XH, Tian M, et al. Long non-coding RNA NEAT1 regulates Hodgkin's lymphoma cell proliferation and invasion via miR-448 mediated regulation of DCLK1. Eur Rev Med Pharmacol Sci. 2020;24(11):6219–6227.
  • Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23.
  • Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.
  • Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–10518.
  • Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225–236.
  • Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016;113(27–28):470–476.
  • Zhou P, Shi J, Wei L, et al. MicroRNA-448 suppresses the proliferation, migration, and invasion of glioma cell line U251 by targeting B-cell lymphoma-2. Chin Med J (Engl). 2020;133(1):114–116.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.